Oppenheimer analyst Michael Wiederhorn assigned a Buy rating to Amedisys (AMED) yesterday and set a price target of $325.00. The company’s shares closed last Wednesday at $281.61.
According to TipRanks.com, Wiederhorn is a top 100 analyst with an average return of 22.3% and a 73.5% success rate. Wiederhorn covers the Healthcare sector, focusing on stocks such as The Ensign Group, Community Health, and HCA Healthcare.
Amedisys has an analyst consensus of Strong Buy, with a price target consensus of $332.29, which is a 18.4% upside from current levels. In a report issued on February 23, Benchmark Co. also maintained a Buy rating on the stock with a $325.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $325.12 and a one-year low of $132.95. Currently, Amedisys has an average volume of 153.8K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Amedisys, Inc. engages in the provision of healthcare services. It operates through the following business segments: Home Health, Hospice, and Personal Care. The Home Health segment delivers services in the homes of individuals who may be recovering from an illness, injury, or surgery. The Hospice segment provides care that is designed to provide comfort and support for those who are facing a terminal illness. The Personal Care segment gives patients assistance with the essential activities of daily living. The company was founded by William F. Borne in 1982 and is headquartered in Baton Rouge, LA.
